News articles about Fibrocell Science (NASDAQ:FCSC) have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fibrocell Science earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.483408800643 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Several research analysts recently weighed in on FCSC shares. Zacks Investment Research upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. HC Wainwright reiterated a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a research report on Friday, June 9th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target (up from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Fibrocell Science has a consensus rating of “Hold” and an average target price of $4.74.

Fibrocell Science (NASDAQ:FCSC) traded up 2.26% during mid-day trading on Tuesday, hitting $3.62. The stock had a trading volume of 92,497 shares. The stock has a 50-day moving average price of $2.93 and a 200 day moving average price of $2.64. Fibrocell Science has a 12-month low of $1.57 and a 12-month high of $4.64. The firm’s market cap is $53.28 million.

Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. Equities analysts anticipate that Fibrocell Science will post ($2.17) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Fibrocell Science (FCSC) Receiving Somewhat Positive Media Coverage, Report Finds” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Insider Buying and Selling by Quarter for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.